Inhibrx Biosciences, Inc. Balance Sheet
INBX / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Inhibrx Biosciences, Inc. had $146M in total assets and $8M in shareholders' equity as of FY2025. Total debt was $101M against $124M in cash, resulting in a $24M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $124.2M | $152.6M | $277.9M |
| Current Assets | $132.8M | $160.4M | $295.4M |
| PP&E (Net) | $3.7M | $6.2M | $6.4M |
| Total Assets | $146.5M | $180.8M | $307.9M |
| Current Liabilities | $33.8M | $40.7M | $56.3M |
| Total Debt | $100.6M | $0 | $207.0M |
| Shareholders' Equity | $8.0M | $43.5M | $43.5M |